以色列 - 希伯来文 - Ministry of Health

teva israel ltd - sunitinib as base - קפסולות - sunitinib as base 25 mg - sunitinib

以色列 - 希伯来文 - Ministry of Health

teva israel ltd - sunitinib as base - קפסולות - sunitinib as base 37.5 mg - sunitinib

以色列 - 希伯来文 - Ministry of Health

teva israel ltd - sunitinib as base - קפסולות - sunitinib as base 50 mg - sunitinib

以色列 - 希伯来文 - Ministry of Health

teva israel ltd - sorafenib as tosylate - טבליות מצופות פילם - sorafenib as tosylate 200 mg - sorafenib

以色列 - 希伯来文 - Ministry of Health

taro international ltd, israel - sunitinib - קפסולה קשיחה - sunitinib 12.5 mg - sunitinib

以色列 - 希伯来文 - Ministry of Health

taro international ltd, israel - sunitinib - קפסולה קשיחה - sunitinib 25 mg - sunitinib

以色列 - 希伯来文 - Ministry of Health

taro international ltd, israel - sunitinib - קפסולה קשיחה - sunitinib 37.5 mg - sunitinib

以色列 - 希伯来文 - Ministry of Health

taro international ltd, israel - sunitinib - קפסולה קשיחה - sunitinib 50 mg - sunitinib

以色列 - 希伯来文 - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

以色列 - 希伯来文 - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.